GlassScriptPhysician profile
Amal Elali
NPI 1023788601
$13,343.49
in general payments reported to CMS, 2019-2025
59 companies · $1,028 in 2025
The $1,028 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $120 · 2022: $3,008 · 2023: $4,036 · 2024: $5,152 · 2025: $1,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,976 · Education: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,975.64 |
| Education | $239.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,399.31 | 2022-2025 | Tecvayli, Darzalex, Talvey |
| Amgen INC. | $1,281.49 | 2022-2025 | Kyprolis, Lumakras, Blincyto |
| Merck Sharp & Dohme LLC | $1,216.47 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $1,043.43 | 2022-2025 | Calquence, Lynparza, Enhertu |
| Novartis Pharmaceuticals Corporation | $890.86 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $547.30 | 2021-2024 | Reblozyl, Opdivo, Opdualag |
| Incyte Corporation | $476.47 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Eisai INC. | $418.01 | 2022-2024 | |
| Gilead Sciences, INC. | $337.57 | 2022-2024 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $335.85 | 2022-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Genentech USA, INC. | $320.05 | 2022-2024 | Tecentriq, Polivy, Phesgo |
| Daiichi Sankyo INC. | $318.77 | 2022-2024 | Enhertu, Vanflyta |
| Lilly USA, LLC | $281.53 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Karyopharm Therapeutics INC. | $278.56 | 2022-2024 | Xpovio |
| Sobi, INC | $262.53 | 2023-2024 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $257.00 | 2022-2025 | Brukinsa |
| Aveo Pharmaceuticals, INC. | $253.87 | 2022-2025 | Fotivda |
| Rigel Pharmaceuticals, INC. | $222.94 | 2023-2025 | Rezlidhia, Tavalisse, Gavreto |
| Regeneron Healthcare Solutions, INC. | $215.06 | 2023-2024 | Libtayo |
| Organon LLC | $202.49 | 2021-2024 | Ontruzant |
| Astellas Pharma US INC | $201.04 | 2024-2025 | Vyloy, Xtandi |
| Celgene Corporation | $187.87 | 2022-2025 | Reblozyl, Opdivo, Opdualag |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.25 | 2022-2025 | Gilotrif |
| Pfizer INC. | $139.17 | 2022-2025 | |
| Adc Therapeutics America, INC. | $137.56 | 2022-2024 | |
| Exelixis INC. | $127.39 | 2022-2024 | Cabometyx |
| Sumitomo Pharma America, INC. | $124.53 | 2023-2025 | Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $114.93 | 2022-2024 | |
| Puma Biotechnology, INC. | $114.61 | 2023-2024 | Nerlynx |
| Abbvie INC. | $100.64 | 2024-2025 | |
| Genzyme Corporation | $99.58 | 2022-2024 | |
| Stemline Therapeutics INC. | $92.33 | 2023-2024 | Orserdu |
| Blueprint Medicines Corporation | $89.41 | 2022-2024 | Ayvakit |
| Emd Serono, INC. | $87.28 | 2024 | |
| Taiho Oncology, INC. | $87.10 | 2022-2024 | |
| Morphosys, US INC. | $74.01 | 2022-2023 | Monjuvi |
| Ipsen Biopharmaceuticals, INC | $69.34 | 2023-2024 | Onivyde, Somatuline Depot |
| Alexion Pharmaceuticals, INC. | $68.25 | 2024 | Ultomiris |
| Coherus Oncology, INC. | $63.48 | 2022-2024 | |
| Deciphera Pharmaceuticals INC. | $57.69 | 2022-2024 | Qinlock |
| Myovant Sciences INC. | $50.38 | 2022 | |
| Glaxosmithkline, LLC. | $49.59 | 2024 | Jemperli, Zejula |
| Seagen INC. | $46.69 | 2022-2023 | Adcetris |
| Recordati_rare_diseases_inc. | $45.24 | 2023 | Sylvant |
| Pharmacyclics LLC, An Abbvie Company | $37.73 | 2022-2023 | Epkinly, Imbruvica |
| Servier Pharmaceuticals LLC | $36.40 | 2024 | |
| Pharmaessentia USA Corporation | $32.45 | 2024 | Besremi |
| Ge Healthcare | $30.05 | 2022 | |
| Kyowa Kirin, INC. | $29.74 | 2023 | Poteligeo |
| Genmab U.S., INC. | $29.18 | 2024 | Epkinly |
| Immunogen, INC. | $28.92 | 2024 | Elahere |
| Cti Biopharma Corp. | $24.77 | 2023 | Vonjo |
| Mylan Institutional INC. | $24.69 | 2023 | Fulphila, Ogivri |
| Jazz Pharmaceuticals INC. | $24.61 | 2025 | |
| Progenics Pharmaceuticals, INC. | $23.01 | 2022 | |
| Mirati Therapeutics, INC. | $22.51 | 2024 | Krazati |
| Uswm, LLC | $22.11 | 2025 | Iwilfin |
| Acrotech Biopharma INC. | $19.23 | 2023 | Beleodaq |
| Chiesi USA, INC. | $17.17 | 2024 | Ferriprox |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amal Elali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.